Switching from IV to subcutaneous infliximab maintenance therapy is associated with high treatment persistence and a stable ...
As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback